AR056470A1 - Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa - Google Patents
Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasaInfo
- Publication number
- AR056470A1 AR056470A1 ARP060103643A ARP060103643A AR056470A1 AR 056470 A1 AR056470 A1 AR 056470A1 AR P060103643 A ARP060103643 A AR P060103643A AR P060103643 A ARP060103643 A AR P060103643A AR 056470 A1 AR056470 A1 AR 056470A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- haloalkyl
- aryl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
Los compuestos de formula (1) son utiles en el tratamiento o la prevencion de trastornos cognitivos, tales como la enfermedad de Alzheimer. La presente además contempla composiciones farmacéuticas que comprenden compuestos de formula (1), métodos de tratamiento de trastornos cognitivos, tales como la enfermedad de Alzheimer, y los intermediarios utiles para la preparacion de los compuestos de formula (1). Reivindicacion 1: Un compuesto de formula (1) sus estereoisomeros, tautomeros, mezclas de estereoisomeros o tautomeros, o sus sales aceptables para uso farmacéutico, donde: el anillo A es arilo, cicloalquilo, heteroarilo o heterocicloalquilo, donde cada anillo está opcionalmente sustituido en una posicion sustituible con halogeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, haloalquilo, haloalcoxi, hidroxilo, hidroxialquilo, CN, ariloxi, -S(O)0-2-(alquilo C1-6), -NR10R11, alcanoílo C1-6, alquil C0-3-CO2R', heteroarilo, heterocicloalquilo, arilo, arilalquilo, o - SO2NR10R11; R1 y R2 se combinan para formar un sistema de anillo [3.3.1] o [3.2.1], donde el N está unido a los dos C puenteados, donde 0 o 1 de los C en el sistema de anillo está opcionalmente reemplazado por un grupo -O-, -S(O)0-2-, o -NR15-, y donde el sistema de anillo [3.3.1] o [3.2.1] está opcionalmente sustituido con 1; 2; 3; o 4 grupos que son, de manera independiente, oxo, halogeno, alquilo C1-6, alquenilo C2-6, haloalquilo C1-6, alquinilo C2-6, hidroxi, hidroxialquilo, alcoxi C1-6, haloalcoxi, -C(O)OR13, -(alquil C1-4)-C(O)OR13, -CONR10R11, -OC(O)NR10R11, -NR'C(O)ORö, -NR'S(O)2Rö, -OS(O)2Rö, -NR'C(O)Rö, CN, =N-R12, o =N-O-R13; dos C adyacentes (sin incluir los C puenteados) en el sistema de anillo [3.3.1] o [3.2.1] se combinan para formar parte de un anillo heteroarilo o heterocicloalquilo fusionado, donde cada uno está opcionalmente sustituido en una posicion sustituible con un grupo seleccionado de manera independiente de alquilo C1-6, cicloalquilo C3-8, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, amino, alquilamino C1-6, dialquilamino C1-6, -S(O)0-2R', hidroxi, hidroxialquilo, halo, haloalquilo C1-2, haloalcoxi C1-2, -NR'C(O)Rö, -NR'SO2Rö, -C(O)R', -C(O)OR', -C(O)alquilOC(O)R'; -C(O)NR10R11, oxo, CN, o alquilfenilo C0-1, donde el fenilo está opcionalmente sustituido con 1 a 5 grupos seleccionados de manera independiente de halogeno, alquilo C1-6, -CO2R', alcoxi C1-6, haloalquilo, haloalcoxi, hidroxilo, CN, NO2, ariloxi, -S(O)0-2-(alquilo C1-6), - NR10R11, alcanoílo C1-6, piridilo, fenilo y -SO2NR10R11, y adicionalmente, dos C adyacentes en el sistema de anillo [3.3.1] o [3.2.1] (sin incluir los C puenteados) pueden combinarse con uno o más grupos -C-, -CH-, o -CH2- a fin de formar un anillo cicloalquilo que, en forma opcional, puede estar sustituido con uno o más grupos que son, de manera independiente, halogeno, alquilo C1-6 o haloalquilo; R10 y R11, en cada aparicion, son de manera independiente H o alquilo C1-6, donde el alquilo está opcionalmente sustituido con un arilo, donde el arilo está opcionalmente sustituido con 1 a 5 grupos que son, de manera independiente, halogeno, hidroxilo, alquilo, alcoxi, haloalquilo, haloalcoxi, CN o NO2; y R10 y R11 juntos pueden formar un anillo de 3-8 miembros, que en forma opcional, incluye un heteroátomo adicional tal como N, O o S; R12 es H, alquilo C1-6 o -SO2-arilo, donde el arilo está opcionalmente sustituido con 1 a 5 grupos que son de manera independiente halogeno, hidroxilo, alquilo, alcoxi, haloalquilo, haloalcoxi, CN o NO2; R13 es H o alquilo C1-6 opcionalmente sustituido con arilo (tal como fenilo o naftilo, más preferentemente, fenilo), hidroxilo o halogeno, donde el arilo está opcionalmente sustituido con 1 a 5 grupos que son de manera independiente halogeno, hidroxilo, alquilo, alcoxi, haloalquilo, haloalcoxi, CN o NO2; R15 es H, arilo, heteroarilo, heterocicloalquilo, -SO2R', -C(O)R', -C(O)OR', o alquilo C1-6 opcionalmente sustituido con arilo, hidroxilo o halogeno, donde los grupos arilo están opcionalmente sustituidos con 1 a 5 grupos que son de manera independiente halogeno, hidroxilo, alquilo, alcoxi, haloalquilo, haloalcoxi, CN, amino, NH(alquilo C1-6), N(alquilo C1-6)(alquilo C1-6) o NO2; y R' y Rö, en cada aparicion, son de manera independiente H, alquilo C1-6, haloalquilo, alqueniloC2-6 o fenilo opcionalmente sustituido con 1 a 5 grupos que son de manera independiente halogeno, alquilo C1-6, -C(O)OR', alcoxi 1-6, haloalquilo, haloalcoxi, hidroxilo, CN, ariloxi, -SO2-(alquilo C1-6), -NR10R11, alcanoílo C1-6, piridilo, fenilo, NO2, o -SO2NR10R11.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70996105P | 2005-08-19 | 2005-08-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056470A1 true AR056470A1 (es) | 2007-10-10 |
Family
ID=37758487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060103643A AR056470A1 (es) | 2005-08-19 | 2006-08-22 | Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa |
Country Status (16)
Country | Link |
---|---|
US (4) | US20110178119A1 (es) |
EP (2) | EP1915371A4 (es) |
JP (2) | JP2009506988A (es) |
KR (1) | KR20080042135A (es) |
CN (2) | CN101426860A (es) |
AR (1) | AR056470A1 (es) |
AU (2) | AU2006283567A1 (es) |
BR (1) | BRPI0614944A2 (es) |
CA (2) | CA2632670A1 (es) |
EC (1) | ECSP088293A (es) |
IL (2) | IL189217A0 (es) |
MX (1) | MX2008002234A (es) |
RU (2) | RU2008110488A (es) |
TW (1) | TW200740806A (es) |
WO (2) | WO2007024651A2 (es) |
ZA (1) | ZA200803521B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
AU2006283567A1 (en) * | 2005-08-19 | 2007-03-01 | Elan Pharmaceuticals, Inc. | Bridged N-bicyclic sulfonamido inhibitors of gamma secretase |
TW200736255A (en) * | 2005-12-01 | 2007-10-01 | Elan Pharm Inc | 5-(Substituted)-pyrazolopiperidines |
BRPI0812014A2 (pt) | 2007-05-25 | 2014-11-18 | Elan Pharm Inc | Pirazolopirrolidinas como inibidores de gama secretase, composição farmacêutica compreendendo as mesmas e uso dos referidos compostos |
CA2696285A1 (en) * | 2007-08-15 | 2009-02-19 | Schering Corporation | Substituted bicyclic piperidinyl- and piperazinyl-sulfonamides useful to inhibit 11.beta.-hydroxysteroid dehydrogenase type-1 |
RU2544856C2 (ru) | 2008-01-25 | 2015-03-20 | Сергей Олегович Бачурин | НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
CN102046625B (zh) | 2008-03-24 | 2015-04-08 | 梅迪维新技术公司 | 桥连杂环化合物及其使用方法 |
PE20110418A1 (es) * | 2008-09-05 | 2011-06-22 | Elan Pharm Inc | Compuestos n-sulfonamido pirazolil policiclicos |
EP2480078A4 (en) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | PYRIDO- [4,3-B] INDOLE AND USE METHOD THEREFOR |
EP2480081A4 (en) | 2009-09-23 | 2013-03-06 | Medivation Technologies Inc | Bridged heterocyclic compounds and methods for their use |
TWI471095B (zh) | 2009-12-21 | 2015-02-01 | Nippon Soda Co | 環胺化合物及殺蟎劑 |
AR081721A1 (es) | 2010-02-25 | 2012-10-17 | Nippon Soda Co | Compuesto de amina ciclica y acaricida |
AU2011293584B2 (en) | 2010-08-23 | 2014-07-31 | Amgen Inc. | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes |
AU2012254158B2 (en) | 2011-02-18 | 2016-02-04 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
WO2013019901A2 (en) * | 2011-08-02 | 2013-02-07 | Buck Institute For Research On Aging | Tropinol esters and related compounds to promote normal processing of app |
EP2690102A1 (en) | 2012-07-24 | 2014-01-29 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bicyclic aza-amides for treatment of psychiatric disorders |
WO2016187772A1 (zh) * | 2015-05-25 | 2016-12-01 | 华为技术有限公司 | 一种光致变色镜头、摄像头及终端设备 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4232158A (en) * | 1979-06-04 | 1980-11-04 | Merck & Co., Inc. | 10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imines |
JPH01132585A (ja) * | 1987-11-17 | 1989-05-25 | Kyowa Hakko Kogyo Co Ltd | Dc−52誘導体 |
US5256656A (en) * | 1990-07-31 | 1993-10-26 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives |
JP3218621B2 (ja) * | 1990-10-11 | 2001-10-15 | 住友化学工業株式会社 | 芳香族系化合物、その製造法およびそれを有効成分とする有害生物防除剤 |
GB9510459D0 (en) * | 1995-05-24 | 1995-07-19 | Zeneca Ltd | Bicyclic amines |
US5795890A (en) * | 1995-09-27 | 1998-08-18 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
EP1006113A1 (en) * | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
SK13532001A3 (sk) * | 1999-04-01 | 2003-02-04 | Pfizer Products Inc. | Aminopiridíny ako inhibítory sorbitoldehydrogenázy |
DK1088819T3 (da) * | 1999-09-30 | 2005-09-12 | Pfizer Prod Inc | 6-azauracilderivater som thyroidreceptorligander |
EP1118612A1 (en) * | 2000-01-21 | 2001-07-25 | Universita Degli Studi di Firenze | Piperazine derivatives possesing nootropic activity |
EP1423119A4 (en) * | 2001-05-10 | 2005-04-13 | Agouron Pharma | HETEROBICYCLES FKBP LIGANDS |
GB0119152D0 (en) | 2001-08-06 | 2001-09-26 | Merck Sharp & Dohme | Therapeutic agents |
TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
HUP0202001A2 (hu) * | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
CA2525124A1 (en) * | 2003-05-13 | 2004-11-25 | Schering Corporation | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
ATE444066T1 (de) * | 2004-06-22 | 2009-10-15 | Schering Corp | Liganden für den cannabinoidrezeptoren |
AU2005307006B2 (en) * | 2004-10-29 | 2012-05-03 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
US7615570B2 (en) * | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
AU2006283567A1 (en) * | 2005-08-19 | 2007-03-01 | Elan Pharmaceuticals, Inc. | Bridged N-bicyclic sulfonamido inhibitors of gamma secretase |
-
2006
- 2006-08-18 AU AU2006283567A patent/AU2006283567A1/en not_active Abandoned
- 2006-08-18 JP JP2008527207A patent/JP2009506988A/ja active Pending
- 2006-08-18 JP JP2008527158A patent/JP2009504773A/ja active Pending
- 2006-08-18 WO PCT/US2006/032261 patent/WO2007024651A2/en active Application Filing
- 2006-08-18 MX MX2008002234A patent/MX2008002234A/es not_active Application Discontinuation
- 2006-08-18 EP EP06801811A patent/EP1915371A4/en not_active Withdrawn
- 2006-08-18 KR KR1020087006687A patent/KR20080042135A/ko not_active Application Discontinuation
- 2006-08-18 WO PCT/US2006/032579 patent/WO2007022502A2/en active Application Filing
- 2006-08-18 CN CNA2006800390519A patent/CN101426860A/zh active Pending
- 2006-08-18 US US12/090,616 patent/US20110178119A1/en not_active Abandoned
- 2006-08-18 CA CA002632670A patent/CA2632670A1/en not_active Abandoned
- 2006-08-18 CA CA002618087A patent/CA2618087A1/en not_active Abandoned
- 2006-08-18 EP EP06813596A patent/EP1916985A4/en not_active Withdrawn
- 2006-08-18 BR BRPI0614944-8A patent/BRPI0614944A2/pt not_active Application Discontinuation
- 2006-08-18 RU RU2008110488/04A patent/RU2008110488A/ru not_active Application Discontinuation
- 2006-08-18 US US11/465,726 patent/US7345056B2/en not_active Expired - Fee Related
- 2006-08-18 CN CNA2006800392764A patent/CN101304997A/zh active Pending
- 2006-08-18 AU AU2006279312A patent/AU2006279312A1/en not_active Abandoned
- 2006-08-18 RU RU2008133306/04A patent/RU2422443C2/ru not_active IP Right Cessation
- 2006-08-21 TW TW095130664A patent/TW200740806A/zh unknown
- 2006-08-22 AR ARP060103643A patent/AR056470A1/es not_active Application Discontinuation
-
2007
- 2007-12-05 US US11/951,097 patent/US7754712B2/en not_active Expired - Fee Related
-
2008
- 2008-02-03 IL IL189217A patent/IL189217A0/en unknown
- 2008-03-18 EC EC2008008293A patent/ECSP088293A/es unknown
- 2008-04-17 IL IL190970A patent/IL190970A0/en unknown
- 2008-04-22 ZA ZA200803521A patent/ZA200803521B/xx unknown
-
2010
- 2010-07-06 US US12/830,914 patent/US20110003802A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056470A1 (es) | Sulfonamidos n- ciclicos puenteados inhibidores de gamma secretasa | |
AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR044116A1 (es) | Compuestos derivados de 5,7 diamino pirazolo [4,3-d] pirimidinas, intermediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la fabricacion de medicamentos. | |
AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
AR074411A1 (es) | Compuestos heterociclicos fungicidas | |
AR074790A1 (es) | Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente. | |
AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
ECSP099461A (es) | Compuesto heteromonocíclico y uso del mismo | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
AR072839A1 (es) | Derivados adamantil diamida y usos de los mismos | |
AR045260A1 (es) | Compuestos que contienen imidazo-oxima sustituidos | |
AR064299A1 (es) | Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos | |
AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
AR062503A1 (es) | Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor. | |
AR069509A1 (es) | Pirido (3,2-e) pirazinas, su procedimiento de preparacion y uso como inhibidores de fosfodiesterasa 10 | |
AR057959A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |